CVRx Q4 2022 Earnings Report $12.90 +0.40 (+3.20%) (As of 12/24/2024 01:48 PM ET) Earnings HistoryForecast CVRx EPS ResultsActual EPS-$0.51Consensus EPS -$0.55Beat/MissBeat by +$0.04One Year Ago EPSN/ACVRx Revenue ResultsActual Revenue$7.18 millionExpected Revenue$6.83 millionBeat/MissBeat by +$350.00 thousandYoY Revenue GrowthN/ACVRx Announcement DetailsQuarterQ4 2022Date1/26/2023TimeN/AConference Call ResourcesPress ReleaseCVRX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW CVRx Earnings HeadlinesCVRx to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 23 at 4:30 PM | globenewswire.comThis device saved a former Mid-South minister from heart failureDecember 19, 2024 | msn.comMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.December 25, 2024 | Brownstone Research (Ad)Strong Growth Outlook for CVRx: Buy Rating Supported by Strategic Adjustments and Market PotentialDecember 17, 2024 | markets.businessinsider.comWilliam Blair Forecasts CVRx's FY2026 Earnings (NASDAQ:CVRX)December 17, 2024 | americanbankingnews.comCVRx price target raised to $22 from $17 at CanaccordDecember 9, 2024 | markets.businessinsider.comSee More CVRx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CVRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CVRx and other key companies, straight to your email. Email Address About CVRxCVRx (NASDAQ:CVRX), a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.View CVRx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
